Evidence map›Paper›PMID 20946065›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2010

High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection.

Christina R Hermos, Pauline Yoong, Gerald B Pier

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Article
  3. In Reply.Deutsches Arzteblatt international · 2023
    Article
  4. Article
  5. Observational
  6. Article
  7. Toxins · 2021
    Review
  8. Evasion of Immunological Memory byFrontiers in immunology · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Christina R HermosDepartment of Medicine, Division of Infectious Diseases, Children's Hospital Boston, Boston, Massachusetts, USA.
Pauline Yoong
Gerald B Pier
Brigham and Women's Hospital · USHarvard University · US

Funding

Virulence and Immunity to StaphylcocciR01AI046706 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI PIER, GERALD B · 2001 to 2010
$4.1M
Pediatric Infectious Diseases Research TrainingT32HD055148 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI WESSELS, MICHAEL R · 2008 to 2018
$2.7M
VIRULENCE AND IMMUNITY TO STAPHYLOCOCCIR21AI046706 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI PIER, GERALD B · 2000 to 2000
$418k
NIAID NIH HHS AI046706NIAID NIH HHS R01 AI046706NIAID NIH HHS R21 AI046706NICHD NIH HHS T32 HD055148
6 · The paper itself

Abstract

backgroundCommunity-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) expressing Panton-Valentine leukocidin (PVL) causes severe skin and soft-tissue infection (SSTI), necrotizing pneumonia, and other invasive infections. The PVL toxin has been implicated as a virulence factor, and antibody to a component of this toxin is under investigation as a vaccine candidate. The role of PVL in pathogenesis remains controversial, and it is unknown whether human serum antibody to PVL modulates infection.

methodsWe determined antibody levels to PVL in serum samples from children aged 0-18 years presenting with polymerase chain reaction-confirmed, PVL-positive MRSA-associated SSTI (with or without prior MRSA infection or SSTI), PVL-positive MRSA invasive infection, and PVL-negative MRSA infection, as well as uninfected control subjects. We also measured antibody-mediated neutralization of PVL-induced lysis of human polymorphonuclear cells.

resultsAntibody to PVL was present in healthy children reaching adult levels by 4-6 years, with a nadir at 3-11 months likely due to loss of maternal antibody. Children with a primary PVL-positive MRSA infection had moderate levels of antibody to PVL that increased after infection. Children with prior MRSA infection or SSTI had high levels of antibody to PVL after the onset of PVL-positive MRSA infection. There was no increase in antibody to PVL in this population's serum samples after the onset of infection. Serum samples from children with PVL-positive MRSA-associated SSTIs, particularly those with prior MRSA infection or SSTI, and convalescent-phase serum samples from children with invasive PVL-positive MRSA infection potently inhibited PVL-induced lysis of polymorphonuclear cells.

conclusionsNeutralizing antibody to PVL does not protect children against primary or recurrent CA-MRSA-associated SSTI.

Indexed as

AdolescentAntibodies, BacterialBacterial ProteinsBacterial ToxinsCells, CulturedChildChild, PreschoolCommunity-Acquired InfectionsExotoxinsFemaleHumansImmunoglobulin GInfantLeukocidinsLeukocytes, MononuclearLogistic ModelsAntibodies, BacterialBacterial ProteinsBacterial ToxinsExotoxinsImmunoglobulin GLeukocidinsleukocidin S-component protein, StaphylococcusLukF protein, Staphylococcus aureusPanton-Valentine leukocidin

Identifiers

PMID20946065
PMCPMC2962716
OpenAlexW1980308311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.